SCHEDULE 1 PROTOCOL FOR COVID-19 VACCINE FACILITY NO-FAULT COMPENSATION SCHEME LIST OF VACCINES

(version dated as of 8. September 2022)

| Vaccine Identifier (International Nonproprietary Name INN) | Brand name of the Vaccine ¹ | Alternative names | Trade name of the Vaccine's manufacturer | Date (dd/mm/yyyy) on which the Vaccine was first was put into circulation by the manufacturer | Scope of Coverage End Point ² of the Vaccine (stated as dd/mm/yyyy) |
|---|--|---|--|---|--|
| Tozinameran | Comirnaty | BNT162b2; Pfizer-BioNTech COVID-19 Vaccine | BioNTech Manufacturing GmbH | 08/12/2020 | 08/12/2022 |
| NA ³ | Vaxzevria | COVID-19 Vaccine (ChAdOx1-S [recombinant]); AZD-1222 | AstraZeneca AB | 04/01/2021 | 04/01/2023 |
| NA | Janssen COVID-19 Vaccine | Janssen Ad26.COV2.S (COVID- 19) vaccine; Coronavirus vaccine-Janssen Pharmaceuticals | Janssen–Cilag International NV | 17/02/2021 | 17/02/2023 |
| Elasomeran | Spikevax | mRNA-1273; Moderna COVID-19 Vaccine | Moderna Biotech | 21/12/2020 | 21/12/2022 |
| NA | NUVAXOVID™ | NUVAXOVID™COVID-19 vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) | Novavax CZ a.s. | 20/12/2021 | 20/12/2023 |

 $^{\scriptsize 1}$ As defined in Section 2 of the Program's Protocol.

² As defined in Section 2 of the Program's Protocol.

³ NA- Not Available